ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2020
CVR: 32323502
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -30,400 and a net result of EUR 196,963 compared with EUR 210,420 the year before. Equity in the 2020 report amounted to EUR 14,601,209. The solvency ratio was 99.9%.
- Gross Profit
- EUR -30,400
- Profit/Loss
- EUR 196,963
- Equity
- EUR 14,601,209
- Total Assets
- EUR 14,611,690
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -30K EUR | 197K EUR | 14.6M EUR | 0 |
| 2019 | - | -2K EUR | 210K EUR | 14.4M EUR | 0 |
| 2018 | - | 7K EUR | 371K EUR | 14.2M EUR | 0 |
| 2017 | - | 257K EUR | -480K EUR | 13.8M EUR | 0 |
| 2016 | - | 3.2M EUR | 3.4M EUR | 14.3M EUR | - |
Official annual report
How creditworthy is ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2019. Gross profit came to DKK -1,850, and the net result was DKK 210,420.
About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.
